Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis

被引:0
作者
L. Fox
M. R. Kramer
I. Haim
R. Priess
A. Metvachuk
D. Shitrit
机构
[1] Rabin Medical Center,Pulmonary Institute
[2] Beilinson Campus,Tuberculosis Center
[3] Maccabi Medical Service,Pulmonary Department, Meir Medical Center, Kfar Saba, Israel; affiliated with Sackler Faculty of Medicine
[4] Tel Aviv University,Pulmonary Institute
[5] Meir Medical Center,undefined
来源
European Journal of Clinical Microbiology & Infectious Diseases | 2011年 / 30卷
关键词
Tuberculosis; Isoniazid; Directly Observe Therapy; Risk Factor Information; Sputum Culture Conversion;
D O I
暂无
中图分类号
学科分类号
摘要
Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN). We describe the demographic and clinical characteristics and risk factor information for persons with IZN monoresistant (resistant to isoniazid) TB compared with drug-susceptible TB and multidrug-resistant (MDR) TB. From 2002 to 2009, 590 cases of TB were diagnosed. Of these, 44 (7.5%) developed MDR-TB and 38 (6.4%) had IZN monoresistant TB. Among the IZN monoresistant TB patients, more common demographic characteristics were former resident of the Soviet Union immigrant, smoker, and previous history of TB (p = 0.005, 0.025, and 0.005, respectively), while HIV, weight loss, and hemoptysis were less common (p = 0.005 for all parameters). The mean length of treatment was 24 ± 4 months for MDR-TB, 10 ± 3 months for IZN monoresistant TB cases, and 8 ± 2 months for all other TB cases. The directly observed therapy (DOT) rate was similar in all three groups. However, treatment failure, completion of TB treatment, and mortality were all similar in drug-susceptible TB and higher in MDR-TB. In multivariate analysis, only a history of previous TB (odds ratio [OR] 1.4; 95% confidence interval [CI]: 1.2–1.6) was significantly associated with IZN monoresistant TB. IZN monoresistant TB has distinct characteristics. However, the length of treatment and outcome are similar to drug-susceptible TB cases.
引用
收藏
相关论文
共 21 条
[1]  
Cattamanchi A(1992)National action plan to combat multidrug-resistant tuberculosis MMWR Recomm Rep 41 5-48
[2]  
Dantes RB(2009)Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis Clin Infect Dis 48 179-185
[3]  
Metcalfe JZ(2008)Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003 Arch Intern Med 168 1984-1992
[4]  
Hoopes AJ(2003)Treatment of tuberculosis [published correction appears in MMWR Recomm Rep. 2005;53(51):1203] MMWR Recomm Rep 52 1-77
[5]  
Kammerer JS(1997)Trends in drug-resistant tuberculosis in the United States, 1993–1996 JAMA 278 833-837
[6]  
Harrington TA(2003)Isoniazid resistance among tuberculosis patients by birth cohort in Germany Int J Tuberc Lung Dis 7 973-979
[7]  
Moore M(2006)The scope and impact of treatment of latent tuberculosis infection in the United States and Canada Am J Respir Crit Care Med 173 927-931
[8]  
Onorato IM(2006)Prevention and control of tuberculosis in correctional and detention facilities: recommendations from CDC. Endorsed by the Advisory Council for the Elimination of Tuberculosis, the National Commission on Correctional Health Care, and the American Correctional Association MMWR Recomm Rep 55 1-44
[9]  
McCray E(2001)Treatment of isoniazid-resistant tuberculosis in southeastern Texas Chest 119 1730-1736
[10]  
Forssbohm M(2002)Antitubercular isoniazid and drug resistance of Arch Pharm (Weinheim) 335 511-525